08/2025. MV130 prevents allergic asthma
Published in Nature Communications, this study demonstrates that MV130 reduces experimental allergic sensitization and prevents eosinophilic airway inflammation.
The findings reveal a novel immunomodulatory approach to reduce allergic sensitization and the development of asthma.
The study evaluates the effect of MV130, a bacterial mucosal vaccine, in a murine model of house dust mite–induced allergic asthma. Vaccination reduces type 2 immune responses, eosinophilic inflammation, and IgE production, restoring normal lung function. In addition, MV130 enhances Th1 and IL-10 responses and provides long-lasting protection, supporting its use as a preventive strategy against allergen-induced asthma.
This study was conducted at the Department of Biochemistry and Molecular Biology, Faculty of Chemistry, Complutense University of Madrid, with the collaboration of INMUNOTEK.










